SynBioBeta Speaker
Johnny Yu
Tahoe Therapeutics
CSO & Co-founder
Johnny Yu is a Co-founder and the Chief Scientific Officer at Vevo Therapeutics. He's focused on scaling frontier sized datasets to power virtual cell models, such as the Tahoe100M dataset. His work sits at the intersection of large-scale single-cell data generation initiatives for drug development across multiple disease indications. He trained at UCSF with Dr. Hani Goodarzi and Dr. Kevan Shokat and holds a PhD from UCSF.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Johnny
This Year
•
-
AIxBIO
Where Does Biology Compute? From Molecular Signals to Clinical Reality
As we move toward the “virtual cell” and ultimately the “virtual organism,” the AIxBIO ecosystem faces a fundamental challenge: where does biology actually compute? While our ability to measure molecular events has advanced dramatically, predicting how those signals translate into emergent, system-level outcomes remains a core bottleneck in programmable biology. This session brings together leaders across AI, synthetic biology, and medicine to explore the computational bottleneck, mapping where predictive power breaks down from molecules to cells to organisms. It will examine how to measure emergence at scale by generating causal, time-resolved, perturbation-rich datasets across diverse biological contexts, and how to close the reality gap with in vivo feedback, using next-generation sensors and real-world data to continuously calibrate and validate models in living systems.
Get a Ticket
•
-
AIxBIO
Where Does Biology Compute? From Molecular Signals to Clinical Reality
As we move toward the “virtual cell” and ultimately the “virtual organism,” the AIxBIO ecosystem faces a fundamental challenge: where does biology actually compute? While our ability to measure molecular events has advanced dramatically, predicting how those signals translate into emergent, system-level outcomes remains a core bottleneck in programmable biology. This session brings together leaders across AI, synthetic biology, and medicine to explore the computational bottleneck, mapping where predictive power breaks down from molecules to cells to organisms. It will examine how to measure emergence at scale by generating causal, time-resolved, perturbation-rich datasets across diverse biological contexts, and how to close the reality gap with in vivo feedback, using next-generation sensors and real-world data to continuously calibrate and validate models in living systems.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
